ADIL ADIAL PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ADIAL PHARMACEUTICALS INC reported revenue of n/a, net income of −$52.0M and diluted EPS of −$11.25; for the fiscal year ended December 2025 revenue was n/a.
ADIL annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$7.80M, net income −$7.98T (margin n/a), EPS −$11.93
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$8.28M, net income −$13.2T (margin n/a), EPS −$68.01
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$6.89M, net income −$5.12T (margin n/a), EPS −$3.60
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$10.9M, net income −$12.7M (margin n/a), EPS −$12.71
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$19.3M, net income −$19.4M (margin n/a), EPS −$1.04
ADIL quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$52.0M, EPS −$11.25
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.02M, EPS −$1.48
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$7.98T, EPS $1.28
- Quarter ended Sep 30, 2025: revenue n/a, net income −$1.79M, EPS −$0.08
- Quarter ended Jun 30, 2025: revenue n/a, net income −$1.96M, EPS −$4.61
- Quarter ended Mar 31, 2025: revenue n/a, net income −$2.23M, EPS −$8.52
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$13.2T, EPS −$64.85
- Quarter ended Sep 30, 2024: revenue n/a, net income −$2.19M, EPS −$0.38
- Quarter ended Jun 30, 2024: revenue n/a, net income −$2.46M, EPS −$0.59
- Quarter ended Mar 31, 2024: revenue n/a, net income −$6.48M, EPS −$2.19
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$5.12T, EPS −$3.27
- Quarter ended Sep 30, 2023: revenue n/a, net income −$1.38M, EPS −$1.18
- Quarter ended Jun 30, 2023: revenue n/a, net income $1.09M, EPS $0.96
- Quarter ended Mar 31, 2023: revenue n/a, net income −$2.91M, EPS −$0.11
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$2.87M, EPS −$5.60
- Quarter ended Sep 30, 2022: revenue n/a, net income −$3.11M, EPS −$3.02
- Quarter ended Jun 30, 2022: revenue n/a, net income −$3.85M, EPS −$3.96
- Quarter ended Mar 31, 2022: revenue n/a, net income −$2.91M, EPS −$0.13
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$5.83M, EPS −$0.27
- Quarter ended Sep 30, 2021: revenue n/a, net income −$4.32M, EPS −$0.22
ADIL cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$6.49M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$6.92M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$6.81M, share buybacks $1.66K
- Fiscal year ended Dec 2022: operating cash flow −$11.2M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$11.9M, share buybacks n/a
ADIL balance sheet
- Jun 30, 2026: cash n/a, total assets $29.1M, total liabilities $28.9M, shareholders' equity −$38.4M
- Mar 31, 2026: cash n/a, total assets $5.23M, total liabilities $1.51M, shareholders' equity $3.72M
- Dec 31, 2025: cash $5.88M, total assets $6.67M, total liabilities $1.40M, shareholders' equity $5.28M
- Sep 30, 2025: cash $4.61M, total assets $5.66M, total liabilities $1.15M, shareholders' equity $4.51M
- Jun 30, 2025: cash $5.91M, total assets $6.80M, total liabilities $1.21M, shareholders' equity $5.59M
- Mar 31, 2025: cash $2.37M, total assets $3.45M, total liabilities $1.32M, shareholders' equity $2.13M
- Dec 31, 2024: cash $3.75M, total assets $5.04M, total liabilities $976K, shareholders' equity $4.07M
- Sep 30, 2024: cash $5.20M, total assets $6.71M, total liabilities $829K, shareholders' equity $5.88M
Is ADIL profitable?
No. ADIAL PHARMACEUTICALS INC lost $7.98T over the last four quarters.
What is ADIL's EPS?
Diluted earnings per share over the last four quarters were −$11.53; −$11.25 in the latest quarter.